Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides^[1]. In Vitro: In Hep G2 cells, Pseudoprotodioscin increases ABCA1 protein and mRNA levels, and promotes the effluxion of ApoA-1-mediated cholesterol. Pseudoprotodioscin inhibits SREBP1c and SREBP2 transcription by decreasing microRNA 33a/b levels. This procedure reciprocally lead to the increase of ABCA1 levels. In THP-1 macrophages, Pseudoprotodioscin shows the similar effect, which reduces HMGCR, FAS and ACC mRNA levels and promotes low density lipoprotein receptor by decreasing the PCSK9 levels^[1].